FDA Adverse Event Other Summary report: N

RADIESSE DERMAL FILLER

MDR report key: 1949215 · Received December 29, 2010

Report

Report Number
2135225-2010-00097
Event Type
Other
Date Received
December 29, 2010
Date of Event
December 1, 2010
Report Date
December 28, 2010
Manufacturer
MERZ AESTHETICS, INC. (FORMERLY BIOFORM MEDICAL, INC.)
Product Code
LMH
PMA / PMN Number
P050052
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
CA, US
Reporter Occupation
NOT APPLICABLE

Narratives

Additional Manufacturer Narrative · 1

THE DEVICE HISTORY RECORDS FOR RADIESSE LOT 1021069 WAS REVIEWED; ALL REQUIRED TESTING SPECIFICATIONS WERE MET PRIOR TO RELEASE AND THERE WERE NO ABNORMALITIES NOTED FOR THESE LOTS.

Description of Event or Problem · 1

A MEDICAL ASSISTANT REPORTED THAT A PT HAD SWELLING AT LEFT NASOLABIAL (NL) FOLD AND LEFT MALAR AREA; AND PAIN WITH CHEWING FOOD AND DRINKING LIQUIDS POST RADIESSE INJECTION. THE PT WAS INJECTED INTO NL FOLDS AND ORAL COMMISSARS ON (B)(6) 2010, AND REPORTED SWELLING AND PAIN DURING A ROUTINE F/U CALL BY THE FACILITY. THE PT SELF TREATED WITH ORAL (B)(6), DOSE AND FREQUENCY WERE UNK. ON (B)(6) 2010, AN UPDATE WAS REC'D FROM THE PHYSICIAN'S OFFICE STATING THAT THE PT WAS SEEN IN THE OFFICE ON (B)(6) 2010, FOR FACIAL SWELLING AND REDNESS. THE PT WAS GIVEN ORAL ANTIBIOTICS FOR AN UNK DIAGNOSIS; NAME, FREQUENCY AND DOSE WERE UNK. IT WAS UNK IF THE ANTIBIOTIC TREATMENT WAS GIVEN TO TREAT A SPECIFIC INFECTION OR IT WAS GIVEN AS A PROPHYLACTIC. PER FACILITY CONTACT, THE PT DID NOT EXHIBIT FEVER, AND THERE WERE NO OPEN AREAS ON HER FACE. ON (B)(6) 2010, ADDITIONAL UPDATE WAS REC'D FROM THE PHYSICIAN'S OFFICE REGARDING THE PT STATUS UPDATE. THE PT WAS GIVEN A 10 DAY SUPPLY OF ORAL CEFALEXIN, DOSE AND FREQUENCY WERE UNK, FOR CELLULITIS AND FULLY RECOVERED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 RADIESSE DERMAL FILLER RADIESSE INJECTABLE IMPLANT LMH MERZ AESTHETICS, INC. (FORMERLY BIOFORM MEDICAL, INC.) 1021069

Patients

Seq Age Sex Outcome Treatment
1 59 YR Required Intervention